Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T Li. Cancer Discov 2020
Times Cited: 98
Times Cited: 98
Shanu Modi, Haeseong Park, Rashmi K Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern, Ian E Krop, Caleb Lee, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Shunji Takahashi. J Clin Oncol 2020
Times Cited: 148
Times Cited: 148
List of shared articles
Times cited
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa,[...]. Clin Cancer Res 2021
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa,[...]. Clin Cancer Res 2021
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Jose Perez, Laia Garrigós, Maria Gion, Pasi A Jänne, Kohei Shitara, Salvatore Siena, Javier Cortés. Expert Opin Biol Ther 2021
Jose Perez, Laia Garrigós, Maria Gion, Pasi A Jänne, Kohei Shitara, Salvatore Siena, Javier Cortés. Expert Opin Biol Ther 2021
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review.
Anna S Linehan, Orla M Fitzpatrick, Patrick G Morris. Breast Cancer (Dove Med Press) 2021
Anna S Linehan, Orla M Fitzpatrick, Patrick G Morris. Breast Cancer (Dove Med Press) 2021
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori,[...]. Clin Cancer Res 2021
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori,[...]. Clin Cancer Res 2021
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse,[...]. Future Oncol 2022
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse,[...]. Future Oncol 2022
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Alice Indini, Erika Rijavec, Francesco Grossi. Int J Mol Sci 2021
Alice Indini, Erika Rijavec, Francesco Grossi. Int J Mol Sci 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez,[...]. Lancet Oncol 2021
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez,[...]. Lancet Oncol 2021
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.
Jacob J Kennedy, Jeffrey R Whiteaker, Laura C Kennedy, Dustin E Bosch, Melissa L Lerch, Regine M Schoenherr, Lei Zhao, ChenWei Lin, Shrabanti Chowdhury, Mark R Kilgore,[...]. Clin Chem 2021
Jacob J Kennedy, Jeffrey R Whiteaker, Laura C Kennedy, Dustin E Bosch, Melissa L Lerch, Regine M Schoenherr, Lei Zhao, ChenWei Lin, Shrabanti Chowdhury, Mark R Kilgore,[...]. Clin Chem 2021
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo. Nat Rev Clin Oncol 2022
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo. Nat Rev Clin Oncol 2022
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.
Ibrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari, Misako Nagasaka. Lung Cancer (Auckl) 2021
Ibrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari, Misako Nagasaka. Lung Cancer (Auckl) 2021
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.
Rupert Bartsch, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Andreas Petzer, Marija Balic, Ursula Pluschnig, Thamer Sliwa, Christian Singer. Wien Klin Wochenschr 2022
Rupert Bartsch, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Andreas Petzer, Marija Balic, Ursula Pluschnig, Thamer Sliwa, Christian Singer. Wien Klin Wochenschr 2022
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Xinling Zhang, Andrew C Huang, Fahai Chen, Hu Chen, Lele Li, Nana Kong, Wenting Luo, Jianmin Fang. Antib Ther 2022
Xinling Zhang, Andrew C Huang, Fahai Chen, Hu Chen, Lele Li, Nana Kong, Wenting Luo, Jianmin Fang. Antib Ther 2022